DOCSLIB.ORG

Uremic Toxins Affect Erythropoiesis During the Course of Chronic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Uremic Toxins Affect Erythropoiesis During the Course of Chronic cells Review Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review Eya Hamza 1, Laurent Metzinger 1,* and Valérie Metzinger-Le Meuth 1,2 1 HEMATIM UR 4666, C.U.R.S, Université de Picardie Jules Verne, CEDEX 1, 80025 Amiens, France; [email protected] (E.H.); [email protected] (V.M.-L.M.) 2 INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), UFR SMBH, Université Sorbonne Paris Nord, CEDEX, 93017 Bobigny, France * Correspondence: [email protected]; Tel.: +33-2282-5356 Received: 17 July 2020; Accepted: 4 September 2020; Published: 6 September 2020 Abstract: Chronic kidney disease (CKD) is a global health problem characterized by progressive kidney failure due to uremic toxicity and the complications that arise from it. Anemia consecutive to CKD is one of its most common complications affecting nearly all patients with end-stage renal disease. Anemia is a potential cause of cardiovascular disease, faster deterioration of renal failure and mortality. Erythropoietin (produced by the kidney) and iron (provided from recycled senescent red cells) deficiencies are the main reasons that contribute to CKD-associated anemia. Indeed, accumulation of uremic toxins in blood impairs erythropoietin synthesis, compromising the growth and differentiation of red blood cells in the bone marrow, leading to a subsequent impairment of erythropoiesis. In this review, we mainly focus on the most representative uremic toxins and their effects on the molecular mechanisms underlying anemia of CKD that have been studied so far. Understanding molecular mechanisms leading to anemia due to uremic toxins could lead to the development of new treatments that will specifically target the pathophysiologic processes of anemia consecutive to CKD, such as the newly marketed erythropoiesis-stimulating agents. Keywords: chronic kidney disease; uremic toxins; anemia; erythropoietin; indoxyl sulfate; iron; erythropoiesis 1. Introduction Chronic kidney disease (CKD) is a global public health problem characterized by a progressive loss of kidney function through the accumulation of uremic toxins leading to inflammation and endothelial dysfunction [1,2]. The European Uremic Toxin (EUTox) Work Group has compiled an authoritative list of 146 compounds as known uremic toxins and classified them into 3 groups based on their physicochemical characteristics such as the molecular weight, protein-binding capacity and removal pattern by dialysis [3–7]. Twenty-five solutes (27.8%) extracted from the sum of these uremic compounds are protein bound and are difficult to remove by dialysis, due to their protein binding capacity [8]. Furthermore, uremic toxins interact negatively with biologic functions when they are not eliminated by the kidneys. This interaction will be described more exhaustively in a further part of the manuscript. Instead of being filtered and excreted by kidney, those uremic toxins accumulate in blood and lead to a deficient erythropoietin (EPO) production by the kidney interstitial fibroblasts (peritubular cells of kidneys), resulting in a defective erythropoiesis due to a decrease in erythrocyte production [9,10]. EPO deficiency and iron deficiency are the main reasons contributing to anemia, a well-known consequence of CKD. In this disease, the best available indicator of kidney function is the glomerular filtration rate (GFR), which estimates the total amount of blood filtered by the kidney that passes Cells 2020, 9, 2039; doi:10.3390/cells9092039 www.mdpi.com/journal/cells Cells 2020, 9, 2039 2 of 18 Cells 2020, 9, x 2 of 19 through the glomeruli per unit of time. Patients with CKD are defined with a GFR inferior to through the glomeruli per unit of time. Patients with CKD are defined with a GFR inferior to 60 60 mL/min/1.73 m2 in the span of at least 3 months while the normal GFR of a healthy person is more mL/min/1.73 m2 in the span of at least 3 months while the normal GFR of a healthy person is more than 90 mL/min/1.73 m2 [11–13]. End-stage renal disease (ESRD) occurs when the kidney function is than 90 mL/min/1.73 m2 [11–13]. End-stage renal disease (ESRD) occurs when the kidney function is belowbelow 15%15% of of its its normal normal capacity. capacity. Some Some of theof the risk risk factors factors that that lead lead to common to common complications complications for CKD for areCKD shown are shown in Figure in Figure1[14–16 1]. [14–16]. FigureFigure 1.1. RiskRisk factorsfactors andand commoncommon complicationscomplications forfor CKD.CKD. InIn pinkpink areare representedrepresented thethe risksrisks factors:factors: familyfamily history history of of CKD, CKD, hypertension, hypertension, diabetes, diabetes, heart disease,heart disease, older age, older and age, racial and and racial ethnic and minorities. ethnic Inminorities. blue are representedIn blue are therepresented common the complications: common complications: anemia, heart anemia, disease, heart mineral disease, and bone mineral disease, and fluidbone buildup,disease, fluid and high buildup, potassium. and high potassium. AmongAmong them,them, anemia,anemia, heartheart disease,disease, mineralmineral andand bonebone diseasedisease (e.g.,(e.g., osteoporosisosteoporosis andand uremicuremic vascularvascular calcification),calcification), highhigh potassiumpotassium (hyperkalemia)(hyperkalemia) andand fluidfluid buildupbuildup (when(when extraextra fluidfluid fromfrom thethe bloodblood are not removed removed by by the the kidneys) kidneys) constitute constitute common common complications complications of ESRD of ESRD [17]. [In17 ].some In somecases, cases,the complications the complications could couldbe the beconsequence the consequence of a strate of agy strategy treatment treatment of a risk of factor. a risk factor.It is the It case is the of casethe development of the development of hyperkalemia of hyperkalemia that is common that is common in patients in patientswith heart with and heart kidney and disease. kidney Because disease. Becauseof the increasing of the increasing use of drugs use of that drugs antagonize that antagonize the renin-angiotensin-aldo the renin-angiotensin-aldosteronesterone system (RAAS), system (RAAS),hyperkalemia hyperkalemia is encountered is encountered frequently frequently in patients in patients with established with established cardiovascular cardiovascular diseases diseases (CVD) (CVD)[18]. [18]. InIn thisthis review,review, wewe mainlymainly focusfocus onon CKD-associatedCKD-associated anemiaanemia asas itit aaffectsffects nearlynearly allall patientspatients withwith ESRDESRD [19[19].]. Anemia Anemia is definedis defined by the by World the HealthWorld OrganizationHealth Organization (WHO) as a(WHO) hemoglobin as a concentration hemoglobin inferiorconcentration to 13 g /inferiordL in men to 13 and g/dL less in than men 12 and g/dL less in than women 12 g/dL [20]. in Numerous women [20]. studies Numerous have reported studies that have a highreported percentage, that a high approximately percentage, half approximately of patients with half ESRD of patients in the with United ESRD States, in the suff Uniteder from States, anemia suffer due tofrom EPO anemia deficiency due [to11 EPO,21,22 deficiency]. As shown [11,21,22]. in Figure As2, accumulationshown in Figure of uremic2, accumulation toxins impairs of uremic renal toxins EPO synthesis,impairs renal compromising EPO synthesis, the growth compromising and differentiation the growth of and red differentiation blood cells (RBCs) of red in blood the bone cells marrow. (RBCs) in the bone marrow. Cells 2020, 9, 2039 3 of 18 Cells 2020, 9, x 3 of 19 Figure 2. Anemia in CKD. Accumulation of of uremic toxi toxinsns induces a decrease of EPO production in thethe kidney. The The decreased EPO synthesis compromise compromisess erythropoeisis in in the bone marrow. This in turnturn results results in in a adecrease decrease of ofRBCs RBCs production production lead leadinging to CKD-associated to CKD-associated anemia. anemia. Abbreviations: Abbreviations: CKD, chronicCKD, chronic kidney kidneydisease; disease;EPO, erythropoietin; EPO, erythropoietin; RBCs, Red RBCs,Blood Cells; Red Blood IS, indoxyl Cells; sulfate; IS, indoxyl PCS, P-cresyl sulfate; sulfate.PCS, P-cresyl sulfate. This in in turn turn results results in in a decrease a decrease of RBCs of RBCs production production leading leading to CKD–associated to CKD–associated anemia. anemia. This exposesThis exposes patients patients to a high-risk to a high-risk for CVD for CVD (patients (patients withwith hypertension hypertension and andheart heart failure), failure), which which are the are mainthe main cause cause of death of death for forthose those patients patients [23,24]. [23,24 ].Among Among them, them, we we note note the the development development and progression of a heart failure and of a a left left ventricular ventricular hypertrophy hypertrophy (LVH) (LVH) that is is commonly commonly associated associated with CKD and anemia [[25]25] (Figure2 2).). The mostmost common common form form of anemia of anemia classically classically seen in CKDseen is in typically CKD normocytic,is typically normochromic, normocytic, normochromic,and hypoproliferative. and hypoproliferative. Actually, anemia Actually, in CKD anem isia a in multifactorial CKD is a multifactorial condition, and condition, asidefrom and asideEPO deficiency,from EPO irondeficiency, is also recognizediron is also as recognized a major contributor as a major in thiscontributor disease [in26 ].this Understanding
Load more

Recommended publications
  • Acute Kidney Injury: Challenges and Opportunities
    Acute kidney injury: Challenges and opportunities Abstract: Community-acquired acute kidney injury (CA-AKI) can be a devastating diagnosis for any patient and can increase mortality during hospitalization. There can be long-term consequences for those who survive the initial insult. This article discusses CA-AKI and its implications for APRNs. By Nhan L.A. Dinh, MSN, CNP, AGACNP-BC, CCRN cute kidney injury (AKI) is a heterogeneous risk of CKD, but if clinicians do not recognize the kidney disorder that increases in-hospital diagnosis, they cannot follow up or intervene. An AKI A morbidity and mortality. In 2016 data, the diagnosis also increases the chance of another AKI incidence of AKI was 20% for Medicare patients with episode, with a 30% risk of a recurrent AKI episode both chronic kidney disease (CKD) and diabetes.1 Us- within 1 year.1 ing Veterans Affairs (VA) 2016 data, AKI occurred in Mortality is increased with an AKI episode. Medi- more than 25% of hospitalized veterans over age 22, care data from 2016 shows an in-hospital mortality of but less than 50% of those with lab-documented AKI 8.2% but this increases to over 13% when includ- were coded as such.1 The chief concern here is a missed ing patients who were discharged to hospice.1 The in- opportunity for intervention. AKI increases long-term hospital mortality for patients without AKI was only Keywords: acute kidney injury (AKI), Acute Kidney Injury Network (AKIN), chronic kidney disease (CKD), community-acquired acute kidney injury (CA-AKI), hospital-acquired acute kidney injury (HA-AKI), Kidney Disease Improving Global Outcomes (KDIGO), SvetaZi / Shutterstock Nephrotoxic Injury Negated by Just-in-time Action (NINJA), sick day rules 48 The Nurse Practitioner • Vol.
    [Show full text]
  • Inherited Renal Tubulopathies—Challenges and Controversies
    G C A T T A C G G C A T genes Review Inherited Renal Tubulopathies—Challenges and Controversies Daniela Iancu 1,* and Emma Ashton 2 1 UCL-Centre for Nephrology, Royal Free Campus, University College London, Rowland Hill Street, London NW3 2PF, UK 2 Rare & Inherited Disease Laboratory, London North Genomic Laboratory Hub, Great Ormond Street Hospital for Children National Health Service Foundation Trust, Levels 4-6 Barclay House 37, Queen Square, London WC1N 3BH, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-2381204172; Fax: +44-020-74726476 Received: 11 February 2020; Accepted: 29 February 2020; Published: 5 March 2020 Abstract: Electrolyte homeostasis is maintained by the kidney through a complex transport function mostly performed by specialized proteins distributed along the renal tubules. Pathogenic variants in the genes encoding these proteins impair this function and have consequences on the whole organism. Establishing a genetic diagnosis in patients with renal tubular dysfunction is a challenging task given the genetic and phenotypic heterogeneity, functional characteristics of the genes involved and the number of yet unknown causes. Part of these difficulties can be overcome by gathering large patient cohorts and applying high-throughput sequencing techniques combined with experimental work to prove functional impact. This approach has led to the identification of a number of genes but also generated controversies about proper interpretation of variants. In this article, we will highlight these challenges and controversies. Keywords: inherited tubulopathies; next generation sequencing; genetic heterogeneity; variant classification. 1. Introduction Mutations in genes that encode transporter proteins in the renal tubule alter kidney capacity to maintain homeostasis and cause diseases recognized under the generic name of inherited tubulopathies.
    [Show full text]
  • Hypertensive Kidney Disease Hypertensive Kidney
    JAMA PATIENT PAGE The Journal of the American Medical Association KIDNEY DISEASE Hypertensive Kidney Disease ypertension (high blood pressure) causes problems for many organs in the body, including the kidneys. Kidney problems Hcaused by high blood pressure (hypertensive kidney disease) occur often in persons who have undetected, untreated, or poorly controlled hypertension. Kidney problems are also called renal dysfunction or renal failure. Certain groups of people, including African Americans and Native Americans, are more at risk for having hypertensive kidney disease. High blood pressure is the second leading cause of kidney failure, surpassed only by diabetes. African Americans are 6 times more likely than whites to have chronic renal failure related to high blood pressure. The November 20, 2002, issue of JAMA includes an article about high blood pressure and its effect on the kidneys. WHY IS HIGH BLOOD PRESSURE DANGEROUS? FOR MORE INFORMATION High blood pressure makes the heart work harder and can also damage the small blood • American Heart Association vessels in the body. These vessels are in all organs of the body, including the kidneys, the 800/242-8721 heart, and the brain. Damage to the arteries (blood vessels that carry blood to organs) www.americanheart.org results in insufficient blood flow to those organs and organ damage. In the kidney, this • National Institute of Diabetes & organ damage is called nephrosclerosis. The kidneys lose their ability to filter blood, Digestive & Kidney Diseases allowing buildup of substances that can be toxic to the body. Eventually the kidneys fail, www.niddk.nih.gov/health/kidney and dialysis (filtration of blood by a special machine) or a kidney transplant becomes /pubs/highblood/highblood.htm necessary to preserve the person’s life.
    [Show full text]
  • Aldosterone Resistance; a Rare Differential Diagnosis for Persistent Hyperkalemia
    MOJ Women’s Health Case Report Open Access Aldosterone resistance; a rare differential diagnosis for persistent hyperkalemia Abstract Volume 5 Issue 5 - 2017 In the human body, Aldosterone is an important hormone for sodium conservation in the kidneys, salivary glands, sweat glands and colon. Aldosterone is synthesized Muhammad Umair, Afsoon Razavi, Zehra exclusively in the zona glomerulosa of the adrenal gland. Significance of aldosterone Tekin, Issac Sachmechi production along with its appropriate action on the receptors is undeniable as far as Department of Medicine, Icahn School of Medicine, USA hemostasis of intracellular and extracellular electrolytes is concerned. Destruction or dysfunction of the adrenal gland in conditions such as primary adrenal insufficiency, Correspondence: Muhammad Umair, Department of congenital adrenal hypoplasia, isolated mineralocorticoid deficiency, acquired Medicine, Icahn School of Medicine at Mount Sinai/NYC Health secondary aldosterone deficiency (hyporeninemic hypoaldosteronism), acquired + Hospital/Queens Jamaica, Diabetes center, 4th floor, Suit primary aldosterone deficiency and inherited enzymatic defects in aldosterone P-432, pavilion building, Queens hospital center, 82-68 164th street, Jamaica, New York, USA, Tel +15163436454, biosynthesis cause clinical symptoms and laboratory characteristics owing to Email [email protected] aldosterone deficiency. Pseudohypoaldosteronism is an aldosterone resistance syndrome i.e. a condition due to insensitivity of target tissues to aldosterone resulting Received: July 25, 2017 | Published: August 09, 2017 in hyponatremia, hyperkalemia and metabolic acidosis. For a proper diagnosis of Aldosterone resistance; serum Sodium levels, serum Potassium levels, ACTH levels, plasma Renin and Aldosterone activity along with serum Cortisol levels play key roles. High doses of Fludrocortisone therapy helps in overcoming aldosterone resistance and assist in maintaining electrolyte balance in the body.
    [Show full text]
  • Glomerulonephritis Management in General Practice
    Renal disease • THEME Glomerulonephritis Management in general practice Nicole M Isbel MBBS, FRACP, is Consultant Nephrologist, Princess Alexandra lomerular disease remains an important cause Hospital, Brisbane, BACKGROUND Glomerulonephritis (GN) is an G and Senior Lecturer in important cause of both acute and chronic kidney of renal impairment (and is the commonest cause Medicine, University disease, however the diagnosis can be difficult of end stage kidney disease [ESKD] in Australia).1 of Queensland. nikky_ due to the variability of presenting features. Early diagnosis is essential as intervention can make [email protected] a significant impact on improving patient outcomes. OBJECTIVE This article aims to develop However, presentation can be variable – from indolent a structured approach to the investigation of patients with markers of kidney disease, and and asymptomatic to explosive with rapid loss of kidney promote the recognition of patients who need function. Pathology may be localised to the kidney or further assessment. Consideration is given to the part of a systemic illness. Therefore diagnosis involves importance of general measures required in the a systematic approach using a combination of clinical care of patients with GN. features, directed laboratory and radiological testing, DISCUSSION Glomerulonephritis is not an and in many (but not all) cases, a kidney biopsy to everyday presentation, however recognition establish the histological diagnosis. Management of and appropriate management is important to glomerulonephritis (GN) involves specific therapies prevent loss of kidney function. Disease specific directed at the underlying, often immunological cause treatment of GN may require specialist care, of the disease and more general strategies aimed at however much of the management involves delaying progression of kidney impairment.
    [Show full text]
  • The Links Between Microbiome and Uremic Toxins in Acute Kidney Injury: Beyond Gut Feeling—A Systematic Review
    toxins Article The Links between Microbiome and Uremic Toxins in Acute Kidney Injury: Beyond Gut Feeling—A Systematic Review Alicja Rydzewska-Rosołowska 1,* , Natalia Sroka 1, Katarzyna Kakareko 1, Mariusz Rosołowski 2 , Edyta Zbroch 1 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (N.S.); [email protected] (K.K.); [email protected] (E.Z.); [email protected] (T.H.) 2 Department of Gastroenterology and Internal Medicine, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Received: 30 October 2020; Accepted: 9 December 2020; Published: 11 December 2020 Abstract: The last years have brought an abundance of data on the existence of a gut-kidney axis and the importance of microbiome in kidney injury. Data on kidney-gut crosstalk suggest the possibility that microbiota alter renal inflammation; we therefore aimed to answer questions about the role of microbiome and gut-derived toxins in acute kidney injury. PubMed and Cochrane Library were searched from inception to October 10, 2020 for relevant studies with an additional search performed on ClinicalTrials.gov. We identified 33 eligible articles and one ongoing trial (21 original studies and 12 reviews/commentaries), which were included in this systematic review. Experimental studies prove the existence of a kidney-gut axis, focusing on the role of gut-derived uremic toxins and providing concepts that modification of the microbiota composition may result in better AKI outcomes. Small interventional studies in animal models and in humans show promising results, therefore, microbiome-targeted therapy for AKI treatment might be a promising possibility.
    [Show full text]
  • Pyelonephritis (Kidney Infection)
    Pyelonephritis (Kidney Infection) Cathy E. Langston, DVM, DACVIM (Small Animal) BASIC INFORMATION urine collected from the bladder to be negative despite infection in the Description kidney. Abdominal x-rays and an ultrasound may be recommended. Bacterial infection of the kidney is termed pyelonephritis . Infection Although culture of a piece of kidney tissue obtained by biopsy may occur within kidney tissue or in the renal pelvis, the area of increases the chance of finding the infection, the invasiveness of the kidney where urine collects before being transported to the the procedure makes it too risky for general use (the biopsy would bladder. need to be taken from deeper within the kidney than the average Causes kidney biopsy). Contrast x-ray studies, such as an excretory uro- In most cases, a urinary tract infection starts in the bladder and gram (intravenous pyelogram), are sometimes helpful. An excre- the bacteria travel upstream to the kidney. Anything that decreases tory urogram involves taking a series of x-rays after a dye (that the free flow of urine, such as obstruction of the urethra (tube shows up white on x-rays) is given intravenously. Other tests may that carries urine from the bladder to the outside), bladder, ureter be recommended to rule out diseases that cause similar clinical (tube that carries urine from the kidney to the bladder), or kid- signs and other causes of kidney disease. ney, increases the risk that the infection will spread to the kid- ney. The presence of stones and growths in the bladder and kidney TREATMENT AND FOLLOW-UP also increases the risk.
    [Show full text]
  • Full Text (PDF)
    www.jasn.org EDITORIALS 5. Grimm PR, Coleman R, Delpire E, Welling PA: Constitutively active Cachexia with muscle wasting is prevalent and closely associated SPAK causes hyperkalemia by activating NCC and remodeling distal with mortality and morbidity in patients with CKD.1 The patho- – tubules. JAmSocNephrol28: 2597 2606, 2017 physiology of muscle wasting in CKD is complex. Inadequate 6. Moriguchi T, Urushiyama S, Hisamoto N, Iemura S, Uchida S, Natsume T, Matsumoto K, Shibuya H: WNK1 regulates phosphorylation of cation- nutritional intake, physical inactivity from muscle weakness, sys- chloride-coupled cotransporters via the STE20-related kinases, SPAK temic inflammation and aberrant signaling of neuropeptides have and OSR1. J Biol Chem 280: 42685–42693, 2005 been implicated.2 To date, there is no effective therapy. Exercise 7. YangSS,MorimotoT,RaiT,ChigaM,SoharaE,OhnoM,UchidaK,LinSH, training has well documented health benefits, including mainte- Moriguchi T, Shibuya H, Kondo Y, SasakiS,UchidaS:Molecularpatho- nance of muscle mass as well as increased physical performance genesis of pseudohypoaldosteronism type II: Generation and analysis of a fi Wnk4(D561A/1) knockin mouse model. Cell Metab 5: 331–344, 2007 resulting from changes in muscle ber phenotype leading to in- 8. Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, Nelson- creased mitochondrial biogenesis. The molecular signaling mech- Williams C, Ellison DH, Flavell R, Booth CJ, Lu Y, Geller DS, Lifton RP: Wnk4 anism underlying adaptations to increased physical activity in controls blood pressure and potassium homeostasis via regulation of mass CKD-associated muscle wasting is not well understood. – and activity of the distal convoluted tubule.
    [Show full text]
  • Urinalysis and Kidney Disease: What You Need to Know
    URINALYSIS AND KIDNEY DISEASE What You Need To Know www.kidney.org About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help your healthcare provider make decisions about your medical treatment? The information in this booklet is based on those recommended guidelines. Stages of Kidney Disease There are five stages of kidney disease. They are shown in the table below. Your healthcare provider determines your stage of kidney disease based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your kidney function. Your treatment is based on your stage of kidney disease. Speak to your healthcare provider if you have any questions about your stage of kidney disease or your treatment. STAGES OF KIDNEY DISEASE Glomerular Stage Description Filtration Rate (GFR)* Kidney damage (e.g., protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR 3 Moderate decrease in GFR 30 to 59 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 *Your GFR number tells your healthcare provider how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. What is a urinalysis (also called a “urine test”)? A urinalysis is a simple test that looks at a small sample of your urine. It can help find conditions that may need treatment, including infections or kidney problems. It can also help find serious diseases in the early stages, like chronic kidney disease, diabetes, or liver disease.
    [Show full text]
  • High Blood Pressure and Chronic Kidney Disease: for People
    HIGH BLOOD PRESSURE AND CHRONIC KIDNEY DISEASE For People with CKD Stages 1–4 www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-KDOQI™) has guidelines and commentaries that help your doctor and healthcare team make important decisions about your medical treatment? The information in this booklet is based on the NKF- KDOQI recommended guidelines and commentaries. What is your stage of kidney disease? There are five stages of kidney disease. They are shown in the table below. Your doctor determines your stage of kidney disease based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your level of kidney function. Your treatment is based on your stage of kidney disease. Speak to your doctor if you have any questions about your stage of kidney disease or your treatment. STAGES of KidNEY DISEASE AGES of KidNEY DISEASE STAGES OF KIDNEY DISEASE Stage Description Glomerular Filtration Rate (GFR)* Kidney damage (e.g., protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR 3 Moderate decrease in GFR 30 to 59 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 *Your GFR number tells your doctor how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. 2 NATIONAL KIDNEY FOUNDATION TABLE of ConTEntS Did you know? ...............................4 What is chronic kidney disease? ................5 What is high blood pressure? ...................6 How are high blood pressure and kidney disease related? ..............................6 How do I know if my blood pressure is too high? ..................................7 How is blood pressure measured? How often should it be checked? ...............8 I have high blood pressure but am not sure if I have CKD.
    [Show full text]
  • Mineralocorticoid-Resistant Renal Hyperkalemia Without Salt Wasting
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 19 (1981), pp. 716—727 Mineralocorticoid-resistant renal hyperkalemia without sal wasting (type II pseudohypoaldosteronism): Role of increased renal chloride reabsorption MORRIS SCHAMBELAN, ANTHONY SEBASTIAN, and FLOYD C. RECTOR, JR. Medical Service and Clinical Study Center, San Francisco General Hospital Medical Center, and the Department of Medicine, Cardiovascular Research Institute, and the General Clinical Research Center, University of California, San Francisco, California Mineralocorticoid-resistant renal hyperkalemia without salt Hyperkaliemie rénale resistant aux minéralocorticoides sans wasting (type II pseudohypoaldosteronism): Role of increased perte de sel (pseudohypoaldostéronisme de type II): Role de l'aug- renal chloride reabsorption. A rare syndrome has been described mentation iie Ia reabsorption de chlore. Un syndrome rare a été in which mineralocorticoid-resistant hyperkalemia of renal origin décrit dans lequel une hyperkaliemie d'origine rénale resistant occurs in the absence of glomerular insufficiency and renal aux minéralocorticoides survient en l'absence de diminution du sodium wasting and in which hyperchioremic acidosis, hyperten- debit de filtration glomerulaire et de perte rénale de sodium et sion, and hyporeninemia coexist. The primary abnormality has dans lequel une acidose hyperchioremique, une hypertension et been postulated to be a defect of the potassium secretory une hyporéninémie coexistent. L'anomalie primaire qui a été mechanism of the distal nephron. The present studies were postulée est un deficit du mécanisme de secretion de potassium carried out to investigate the mechanism of impaired renal du nephron distal. Ce travail a etC entrepris pour étudier le potassium secretion in a patient with this syndrome.
    [Show full text]
  • What Is Lupus Nephritis
    What is lupus nephritis (LN)? Lupus nephritis (LN) is inflammation of the kidney that occurs as a common symptom of systemic lupus erythematosus (SLE), also known as lupus. Proteins in the immune system called antibodies damage important structures in the kidney. ⅱ Why are the kidneys important? To understand how lupus nephritis damages the kidney, it is important to understand how the kidneys work. The kidneys’ main function is to filter out excess waste and water from the blood through the urine. Kidneys also balance the salts and minerals circulating in the blood, help control blood pressure and make red blood cells. So, when the kidneys are damaged or fail, they can’t do their job as well. As a result, the kidneys are not able to filter out waste and water into the urine causing it to stay in the blood. What are the signs and symptoms of LN? Signs to ask the doctor about include blood in the urine or foamy urine which can mean that there is excess protein. Other signs to notice are swelling of legs, ankles, hands or tissue around the eyes as well as weight gain that can be caused by fluid the body isn’t getting rid of. ⅲ Symptoms of lupus nephritis also include high blood pressure, joint/muscle pain, high levels of waste (creatinine) in the blood, or impaired/failing kidney. ⅳ How common is LN? Lupus nephritis is the most common complication of lupus. Five out of 10 adults with lupus will have lupus nephritis, while eight out of 10 children with lupus will have kidney damage, which usually stems from lupus nephritis.
    [Show full text]